Losmapimod

• Description :

  Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively[1].

• Product Name Alternative :

  GSK-AHAB; GW856553X; SB856553

• UNSPSC :

  12352005

• Hazard Statement :

  H361

• Target :

  Autophagy; p38 MAPK

• Type :

  Reference compound

• Related Pathways :

  Autophagy; MAPK/ERK Pathway

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Losmapimod.html

• Concentration :

  10mM

• Purity :

  99.94

• Solubility :

  DMSO : 27.5 mg/mL (ultrasonic) |Ethanol : 33.33 mg/mL (ultrasonic)

• Smiles :

  CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F

• Molecular Formula :

  C22H26FN3O2

• Molecular Weight :

  383.46

• Precautions :

  H361

• References & Citations :

  [1]Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330 (3) :964-70.|[2]Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [585543-15-3]